Abstract
Background: Tumour microenvironment is recognized as a major determinant of intrinsic resistance to anticancer therapies. In solid tumour types, such as breast cancer, lung cancer and pancreatic cancer, stromal components provide a fibrotic niche, which promotes stemness, EMT, chemo- and radioresistance of tumour. However, this microenvironment is not recapitulated in the conventional cell monoculture or xenografts, hence these in vitro and in vivo preclinical models are unlikely to be predictive of clinical response; which might attribute to the poor predictively of these preclinical drug-screening models.
Conclusion: In this review, we summarized recently developed co-culture platforms in various tumour types that incorporate different stromal cell types and/or extracellular matrix (ECM), in the context of investigating potential mechanisms of stroma-mediated chemoresistance and evaluating novel agents and combinations. Some of these platforms will have great utility in the assessment of novel drug combinations and mechanistic understanding of the tumor-stroma interactions.Keywords: Tumour microenvironment, drug development, tumour-stroma crosstalk, co-culture, cancer, anti-cancer drug.
Combinatorial Chemistry & High Throughput Screening
Title:Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade
Volume: 20 Issue: 5
Author(s): Ruiling Xu*Frances M. Richards
Affiliation:
- West China School of Medicine, Sichuan University, Chengdu, 610041,China
Keywords: Tumour microenvironment, drug development, tumour-stroma crosstalk, co-culture, cancer, anti-cancer drug.
Abstract: Background: Tumour microenvironment is recognized as a major determinant of intrinsic resistance to anticancer therapies. In solid tumour types, such as breast cancer, lung cancer and pancreatic cancer, stromal components provide a fibrotic niche, which promotes stemness, EMT, chemo- and radioresistance of tumour. However, this microenvironment is not recapitulated in the conventional cell monoculture or xenografts, hence these in vitro and in vivo preclinical models are unlikely to be predictive of clinical response; which might attribute to the poor predictively of these preclinical drug-screening models.
Conclusion: In this review, we summarized recently developed co-culture platforms in various tumour types that incorporate different stromal cell types and/or extracellular matrix (ECM), in the context of investigating potential mechanisms of stroma-mediated chemoresistance and evaluating novel agents and combinations. Some of these platforms will have great utility in the assessment of novel drug combinations and mechanistic understanding of the tumor-stroma interactions.Export Options
About this article
Cite this article as:
Xu Ruiling*, Richards M. Frances , Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade, Combinatorial Chemistry & High Throughput Screening 2017; 20 (5) . https://dx.doi.org/10.2174/1386207320666170202093538
DOI https://dx.doi.org/10.2174/1386207320666170202093538 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Interaction of Oligomeric Breast Cancer Resistant Protein (BCRP) with Adjudin: A Male Contraceptive with Anti-Cancer Activity
Current Molecular Pharmacology Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design ExomeHMM: A Hidden Markov Model for Detecting Copy Number Variation Using Whole-Exome Sequencing Data
Current Bioinformatics Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology Microfluidic Devices for Circulating Tumor Cells Isolation and Subsequent Analysis
Current Pharmaceutical Biotechnology Metabolic and Amino Acid Alterations of the Tumor Microenvironment
Current Medicinal Chemistry Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Editorial [Hot Topic: Calcium Metabolism and Treatment of Hypercalcemia]
Medicinal Chemistry Editorial Review 2015
Current Radiopharmaceuticals The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy CD248: Reviewing its Role in Health and Disease
Current Drug Targets Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Stem Cell-based Treatment Strategies for Degenerative Diseases of the Retina
Current Stem Cell Research & Therapy